This recommendation partly reflects the reduction in MACE outcomes and lower rates of hospitalization for HF consistently observed in the subgroup of patients with CKD randomized to receive an SGLT2 inhibitor in recent trials, including the CANagliflozin cardioVascular Assessment Study (CANVAS) Program (30), DECLARE-TIMI (31), DAPA-HF (32), EMPEROR-Reduced (33, 34) and EMPEROR-Preserved (35) (Supplementary Table 1, see section on supplementary materials given at the end of this article). The gene discussed is SLC5A2; the disease is chronic kidney disease.